T cell-based immune response (CMI)

T cell-based immune responses represent the cellular arm of the adaptive immune system, primarily mediated by T lymphocytes that recognize antigens presented by major histocompatibility complex (MHC) molecules (Wikipedia). These responses involve complex signaling cascades leading to T-cell activation, expansion, and the execution of effector functions such as direct cell lysis by cytotoxic T cells or cytokine secretion by helper T cells (StatPearls, 2023). In therapeutic contexts, T cell responses are pivotal for anti-tumor immunity, where checkpoint inhibitors like PD-1 or CTLA-4 blockers are used to reinvigorate exhausted T cells to target cancer cells (NIH, 2023). Conversely, pharmacological suppression of these responses is a primary strategy in treating autoimmune diseases and preventing organ transplant rejection to avoid tissue damage (PubMed). Because 'T cell-based immune responses' describes a broad physiological category rather than a single molecular entity like a receptor or enzyme, it is classified as a biological process rather than a discrete drug target (UniProt). Clinical modulation of these responses requires careful monitoring due to the risk of severe side effects, such as cytokine release syndrome or immune-related adverse events targeting healthy tissues.

Other names

Cell-mediated immunityT-cell mediated immunityAdaptive T-cell responseCellular immune response

Modulation of T-lymphocyte activation, expansion, and effector functions through molecular pathways such as immune checkpoint inhibition, calcineurin inhibition, costimulation blockade, or the use of genetically engineered T-cell receptors.